Picture2.jpg
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
April 22, 2021 07:51 ET | ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, April 22, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the...
Picture2.jpg
ASLAN Pharmaceuticals Announces Pricing of Public Offering of American Depositary Shares
March 03, 2021 00:42 ET | ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, March 03, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the...
Picture2.jpg
ASLAN Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares
March 01, 2021 16:01 ET | ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, March 01, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the...
ASLAN Pharmaceuticals Announces $18 Million Private Placement
February 25, 2021 06:30 ET | ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, Feb. 25, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the...
New Research Published in Toxicology in Vitro Provides Insight Into the Hepatotoxicity of DHODH Inhibitors Suggesting ASLAN003 Has the Potential to Be Best-In-Class
January 26, 2021 07:30 ET | ASLAN PHARMACEUTICALS LIMITED
— New research shows ASLAN003 to have the lowest potential for hepatotoxicity of the compounds tested despite being one of the most potent DHODH inhibitors — Data differentiates ASLAN003 from first...
ASLAN Pharmaceuticals Opens Expansion Cohort in ASLAN004 Atopic Dermatitis Clinical Trial
January 11, 2021 05:34 ET | ASLAN PHARMACEUTICALS LIMITED
- ASLAN has completed recruitment of patients into the third, highest dose cohort of ASLAN004 in AD patients. ASLAN004 was found to be well tolerated at all dose levels - Data Monitoring...
ASLAN Pharmaceuticals to Present at Upcoming Piper Sandler Investor Conference
November 19, 2020 07:22 ET | ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, Nov. 19, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the...
ASLAN Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
November 09, 2020 07:00 ET | ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, Nov. 09, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the...
ASLAN Pharmaceuticals Initiates Third Dose Cohort of ASLAN004 in Atopic Dermatitis Clinical Trial
October 22, 2020 07:30 ET | ASLAN PHARMACEUTICALS LIMITED
--   ASLAN has initiated recruitment of patients into third dose cohort at sites in the US, Australia and Singapore following successful safety review of second cohort --   ASLAN004 found to be...
ASLAN Pharmaceuticals to Develop ASLAN003 as Next Generation DHODH Inhibitor in Autoimmune Conditions
October 16, 2020 05:25 ET | ASLAN PHARMACEUTICALS LIMITED
--  ASLAN believes ASLAN003 has the potential to be the most potent oral inhibitor of DHODH currently in development for autoimmune disease, more than 30 times more potent at inhibiting the DHODH...